Detail akcie ProMIS Neurscnc Rg online

Business Summary: ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Promis Neurosciences Inc revenues was not reported. Net loss totaled $29M vs. income of $3M. Net loss reflects Medicine Solutions segment loss increase from $10.8M to $29.4M, Canada segment loss increase from $10.8M to $29.4M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.25 to -$18.46.